Antibacterial Drugs: Market Research Report

April 2010 | 719 pages | ID: A95271B8C98EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Antibacterial Drugs in US$ Million by the following drug classes: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Other Antibacterial Drugs.

The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2006 through 2015.

The report profiles 124 companies including many key and niche players such as Abbott Laboratories, AstraZeneca PLC, Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Pfizer, Inc., and Wyeth Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Cephalosporins
Penicillins
Fluoroquinolones
Macrolides
Other Antibacterial Drugs

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

Global Market Outlook
Antibacterial Resistance – A Key Growth Dampener
Antibacterial Resistance Costs High
Patent Expiries Commoditize Antibacterials Market
Patent Expiries of Major Anti-Bacterial Drugs
Generic Competition Intensifies
Cephalosporins Dominate the Anti-bacterials Market

Table 1. Worldwide Market for Anti-Bacterials by Major Drug Class (2010): Percentage Share Breakdown for Cephalosporins, Penicillins, Fluoroquinolones ,Macrolides, and Others (includes corresponding Graph/Chart)

Macrolides and Fluoroquinolones to Grow At a Faster Rate
Major Players and Key Brands

Table 2. Select Major Anti-Bacterial Drugs Worldwide (2008 & 2007): Value Sales in US$ Million for Levaquin/ Floxin, Zosyn/Tazocin, Zyvox, Augmentin, Merrem, Primaxin, Avelox/Avalox, Cravit, Zithromax/Zmax, Cipro/ Ciprobay, Rocephin (includes corresponding Graph/Chart)

United States Leads the Global Market, Other Regions to Exhibit Faster Growth
Injectables Gain Traction

2.ANTI-BACTERIAL DRUG CLASSES – A REVIEW

Cephalosporins
Select Major Cephalosporins Worldwide
List of Select Cephalosporin Drugs by Generation
Drug Details of Select Cephalosporins
Omnicef (Abbott Laboratories)
Rocephin (Roche)
Maxipime (Bristol Myers Squibb/Elan)
Zinnat (GlaxoSmithKline)
Spectracef (Cornerstone BioPharma)
Fluoroquinolones
Select Major Fluoroquinolones Worldwide
Drug Details of Select Fluoroquinolones
Levaquin/Floxin/Cravit (Ortho-McNeil-Janssen/ Daiichi Sankyo)
Brand Names of Levofloxacin in Different Regions
Avelox (Bayer)
Ciprofloxacin (Various)
Macrolides
Drug Details of Select Macrolides
Biaxin (Abbott)
Zmax (Pfizer Inc.)
Penicillins
Select Penicillins Worldwide

Table 3. Sales of Leading Penicillin Drugs in US$ Million (2006-2008) (includes corresponding Graph/Chart)

Drug Details of Select Penicillins
Augmentin (GlaxoSmithKline)
Zosyn (Wyeth)
Other Anti-bacterial Drugs
Other Select Anti-bacterials Worldwide
Details of Other Select Anti-bacterial Drugs Worldwide
Zyvox (Pfizer)
Cubicin (Cubist Pharmaceuticals)
Targocid (Sanofi-Aventis/Astellas)
Vancomycin (Eli Lilly)
Carbapenems
Faropenem (Replidyne)
Primaxin (Merck & Co.)
Merrem/Meronem (AstraZeneca)

3.AN OVERVIEW OF BACTERIAL INFECTIONS AND TREATMENT

Bacterial Infections
Types of Bacteria and Bacterial Infections
Overview of Select Bacterial Infections
Pneumonia
Intra-Abdominal Infections
Central Nervous System Infections
Bloodstream Infections
Bone Infections
Surgical Site Infections
Urinary Tract Infections
Urethritis
Hemorrhagic Cystitis
Acute Pyelonephritis
Anti-bacterial Drugs to Combat Against Bacteria
Launch Year of Different Anti-Bacterial Drug Classes
Anti-bacterial Categorization
Classification Based on Action Mechanism
Classification Based on Method of Suppressing Bacterial Growth
Bactericidal Drugs
Bacteriostatic Drugs
Classification Based on Spectra of Activity
Anti-Bacterial Drug Classes and their Uses
Cephalosporins
Treatment
Side Effects
Penicillins
History
Types of Penicillins
Side Effects
Fluoroquinolones
Treatment
Major Fluoroquinolones Worldwide, Along with Indications
Side Effects
Macrolides
Select Macrolides and its Derivatives by Development Stage (As of 2008)
Treatment
Side Effects
Other Antibacterials
Aminoglycosides
Treatment
Aminoglycosides and Indications
Side Effects
Tetracyclines
Treatment
Side Effects
Sulfonamides
Treatment
Effects of the Drug
Mupirocin
Carbepenems
Aztreonam
Glycopeptides
Vancomycin
Teicoplanin
Bacitracin
Lincosamines
Polymyxins
Chloramphenicol
Limitations of Antibacterial Therapy
Bacterial Resistance
Antibacterial-Resistant Bacteria by Type
Cross-resistance
Phage Therapy, a Promising Approach for Bacterial Infections
Treatment and Application of Phase Therapy
Phages for Antibiotic-Resistant Bacteria
Companies Involved in Phage Therapy Research

4.PRODUCTS INTRODUCTIONS/APPROVALS/ CLINICAL TRIALS

Johnson & Johnson Receives Complete Response Letter for Ceftobiprole from US FDA
Negative Opinion on Ceftobiprole by European CHMP
Theravance and Astellas Obtains FDA Approval for VIBATIV™ for Treating Complicated Skin and Skin Structure Infections (cSSSI)
Daiichi Sankyo Company Introduces Cravit® Formulations
Forest Labs Announces Encouraging Phase III Results of Ceftaroline
Cubist Pharma Initiates First-In-Human Clinical Trial with CB-183,315
Basilea Pharmaceutica Announces New Research Results for BAL30072 in Multi- Resistant Gram- Negative Bacteria
Galderma Laboratories Launches Epiduo™ Gel for Acne Treatment
Destiny Pharma Develops New Metallo-Porphyrin Anti-Bacterial Drug
US FDA Asks Arpida to Secure Additional Data for Iclaprim
MiddleBrook Obtains FDA Approval for MOXATAG™
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin
Watson Pharma Introduces Biaxin XL’s Generic Version
Taisho Toyama Pharmaceutical Rolls Out Zosyn® to Treat Severe Bacterial Infections
GSK Launches ALTARGO® in the UK
Daiichi Obtains Approval for Gracevit®
New Research Backs LEVAQUIN Use in CAP Treatment in Concordance with Guidelines
FDA Instructs Targanta to Conduct Additional Oritavancin Trials
J&J’s Doribax Obtains FDA Approval for Urinary Tract and Intra-abdominal Infections
APL Receives FDA Approval for Cefpodoxime Proxetil
Toyama Launches New Garenoxacin Quinolone Antibiotic
Wockhardt to Introduce Cefprozil Tablets in the US
MSD India Launches Invanza in India
Macrolide Antibiotic Developed in the US
GSK Obtains EC Approval for Altargo® in Treating Skin Infections

5.RECENT INDUSTRY ACTIVITY

Pfizer Indicts Teva for Zyvox Patent Infringement
Beactica and Cubist Sign Agreement to Develop Advanced Anti-Bacterials
Jiangchuan Pharmaceutical Forges Joint Venture with Sichuan Mingxin
Forest Laboratories Collaborates with AstraZeneca to Co-Develop Ceftaroline
TB Alliance Enters into Multiple Deals for TB Drug Discovery
Kemin Industries Acquires Amalyte Pharmaceuticals
Forma Therapeutics Sign Deal with Cubist to Make Antibacterial Drugs
Lee's Pharmaceutical Holdings Acquires Rights to Oral Antibacterial Drug
Anacor Pharmaceuticals Collaborates with TB Alliance
Jiangchuan Pharmaceutical Forges Joint Venture with Sichuan Mingxin
Evotec and Cubist Ink Research Pact for Fragment-Based Drug Discovery
Abbott Acquires Ibis Biosciences
Elder and Strides on Expansion Mode
Pfizer Inks Agreements with Claris Lifesciences and Aurobindo Pharma
Akorn Signs Agreement with Eli Lilly and Company
NovaBay Inks Agreement with Medical University of Innsbruck
Tibotec Collaborates with Global Alliance for TB Drug Development
Sandoz Introduces Generic Maxipime®
Merck and Ranbaxy to Launch Anti-Bacterial and Anti-Fungal Drugs
Wyeth Receives an Approvable Letter from US FDA for TYGACIL®
Mylan Receives FDA Approval for Linezolid 600 mg Tablets
Rottapharm/Madaus Obtains Clearance to Market ProQuin XR in Sweden
MiddleBrook Obtains NDA Approval for MOXATAG™
ULL Establishes New Antibiotics Unit in Himachal Pradesh
Biocat to Expand Presence in the Indian Market
Novartis to Acquire Protez
Orchid Signs Licensing Agreement with Merck
Forest and Novexel Sign Licensing Agreement
Sanofi-aventis Collaborates with Novozymes
AstraZeneca Acquires Arrow Therapeutics
Cubist Submits INDs for CB-182,804 and CB-183,315
GlaxoSmithKline Enters into Strategic Alliance with Mpex Pharmaceuticals to Develop Novel Drugs to treat Bacterial Diseases
Advanced Life Sciences and Wyeth Pharmaceuticals Sign Marketing Deal for Commercialization of Cethromycin in Asia Pacific
GlaxoSmithKline Receives FDA Approval for Altabax
GSK and Anacor Team Up for Boron Chemistry-Based Antibiotics and Antivirals
Cubist Pharmaceuticals Receives Health Canada Approval for CUBICIN®
Cubist Obtains Approval to Market CUBICIN for Added Indications in EU
Cubist Gains Approval for CUBICIN in Taiwan and South Korea
Cethromycin Achieves FDA’s Orphan Drug Designation
GSK Receives Approval for ALTARGO® in Europe
sanofi-aventis Updates Prescription Information for Ketek in the US

6.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)
AstraZeneca PLC (UK)
Bayer HealthCare AG (Germany)
Bristol-Myers Squibb Co. (USA)
Cubist Pharmaceuticals, Inc. (USA)
Daiichi Sankyo Company, Ltd. (Japan)
GlaxoSmithKline Plc. (UK)
Johnson & Johnson (USA)
Pfizer, Inc. (US)
Wyeth Pharmaceuticals, Inc. (US)

7.GLOBAL MARKET PERSPECTIVE

Table 4. World Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 5. World 10-Year Perspective for Antibacterial Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

Table 6. World Recent Past, Current & Future Analysis for Cephalosporins by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 7. World 10-Year Perspective for Cephalosporins by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

Table 8. World Recent Past, Current & Future Analysis for Penicillins by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 9. World 10-Year Perspective for Penicillins by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

Table 10. World Recent Past, Current & Future Analysis for Fluoroquinolones by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 11. World 10-Year Perspective for Fluoroquinolones by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

Table 12. World Recent Past, Current & Future Analysis for Macrolides by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 13. World 10-Year Perspective for Macrolides by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

Table 14. World Recent Past, Current & Future Analysis for Other Anti-bacterial Drugs by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 15. World 10-Year Perspective for Other Anti-bacterial Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. MARKET ANALYSIS

Current & Future Analysis
Products Approvals/Launches/Clinical Trials
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 16. US Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class – Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 17. US 10-Year Perspective for Antibacterial Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

2.EUROPE

A. MARKET ANALYSIS

Current and Future Analysis
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 18. European Recent Past, Current & Future Analysis for Antibacterial Drugs by Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 19. European 10-Year Perspective for Antibacterial Drugs by Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart)

Table 20. European Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class- Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 21. European 10-Year Perspective for Antibacterial Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

2A.FRANCE

A. MARKET ANALYSIS

Antibiotics Use Takes A Dip, As Regulatory Authorities’ Efforts Pays Off

B. MARKET ANALYTICS

Table 22. French Recent Past, Current & Future Analysis for Antibacterial Drugs- Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2B.GERMANY

A. MARKET ANALYSIS

Key Player
Bayer HealthCare AG

B. MARKET ANALYTICS

Table 23. German Recent Past, Current & Future Analysis for Antibacterial Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2C.ITALY

Market Analysis

Table 24. Italian Recent Past, Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2D.THE UNITED KINGDOM

A. MARKET ANALYSIS

Infectious Diseases – A Quick Primer
Research and Development of New Anti-Infectives
Products Introduction
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 25. UK Recent Past, Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2E.SPAIN

Market Analysis

Table 26. Spanish Recent Past, Current & Future Analysis for Antibacterial Drugs-Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2F.REST OF EUROPE

A. MARKET ANALYSIS

Strategic Corporate Development
Key Player
F. Hoffmann-La Roche, Ltd. (Switzerland)

B. MARKET ANALYTICS

Table 27. Rest of Europe Recent Past Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3.ASIA-PACIFIC

A. MARKET ANALYSIS

Focus on Select Regional Markets
China
Carbapenem Antibiotics Hold Great Potential
India
Injectable Antibiotics Demonstrate Robust Growth
New Initiative to Develop Novel Antibiotic Molecules
Products Introductions/Developments
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 28. Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class – Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 29. Asia-Pacific 10-Year Perspective for Antibacterial Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

4.REST OF WORLD

A. MARKET ANALYSIS

Strategic Corporate Developments

B. MARKET ANALYTICS

Table 30. Rest of World Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class – Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 31. Rest of World 10-Year Perspective for Antibacterial Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Other Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled:124 (including Divisions/Subsidiaries - 127)
Region/CountryPlayers
The United States26
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)